- Home
- NXTC vs CLSD Comparison
NXTC vs CLSD Comparison
Compare NXTC & CLSD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- CLSD
- Stock Information
- Founded
- NXTC 2015
- CLSD 2011
- Country
- NXTC United States
- CLSD United States
- Employees
- NXTC N/A
- CLSD N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- CLSD Biotechnology: Pharmaceutical Preparations
- Sector
- NXTC Health Care
- CLSD Health Care
- Exchange
- NXTC Nasdaq
- CLSD Nasdaq
- Market Cap
- NXTC 24.6M
- CLSD 20.4M
- IPO Year
- NXTC 2019
- CLSD 2016
- Fundamental
- Price
- NXTC $8.71
- CLSD $3.68
- Analyst Decision
- NXTC Strong Buy
- CLSD Hold
- Analyst Count
- NXTC 3
- CLSD 4
- Target Price
- NXTC $23.00
- CLSD $65.00
- AVG Volume (30 Days)
- NXTC 85.8K
- CLSD 32.8K
- Earning Date
- NXTC 11-05-2025
- CLSD 11-07-2025
- Dividend Yield
- NXTC N/A
- CLSD N/A
- EPS Growth
- NXTC N/A
- CLSD N/A
- EPS
- NXTC N/A
- CLSD N/A
- Revenue
- NXTC N/A
- CLSD $4,166,000.00
- Revenue This Year
- NXTC N/A
- CLSD $98.20
- Revenue Next Year
- NXTC N/A
- CLSD $213.77
- P/E Ratio
- NXTC N/A
- CLSD N/A
- Revenue Growth
- NXTC N/A
- CLSD N/A
- 52 Week Low
- NXTC $2.69
- CLSD $3.32
- 52 Week High
- NXTC $19.20
- CLSD $17.40
- Technical
- Relative Strength Index (RSI)
- NXTC 46.50
- CLSD 48.45
- Support Level
- NXTC $8.51
- CLSD $3.70
- Resistance Level
- NXTC $10.56
- CLSD $4.14
- Average True Range (ATR)
- NXTC 1.23
- CLSD 0.29
- MACD
- NXTC -0.36
- CLSD -0.07
- Stochastic Oscillator
- NXTC 1.93
- CLSD 14.04
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
About CLSD Clearside Biomedical Inc.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.